Similarly, studies using the NLRP-3 inflammasome inhibitor, MCC950, resulted in slowing the development of HF in both models of myocardial infarction (MI) and pressure overload by suppressing IL-1β release [84]. Here, NLRP3 is linked to hydrops fetalis.